Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes-Reference-Cited by-同舟云学术

Pharmacokinetics and Pharmacodynamics of the Long-Acting Insulin Analog Glargine After 1 Week of Use Compared With Its First Administration in Subjects With Type 1 Diabetes

Published:2007-05-01 Issue:5 Volume:30 Page:1261-1263
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Porcellati Francesca¹,Rossetti Paolo¹,Ricci Natalia Busciantella¹,Pampanelli Simone¹,Torlone Elisabetta¹,Campos Susana Hernandez¹,Andreoli Anna Marinelli¹,Bolli Geremia B.¹,Fanelli Carmine G.¹

Affiliation:

1. Department of Internal Medicine, Section of Internal Medicine, Endocrinology, and Metabolism, University of Perugia, Perugia, Italy

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/30/5/1261/597075/zdc00507001261.pdf

Reference16 articles.

1. Bolli GB, Di Marchi R, Park G, Pramming S, Koivisto VA: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 42: 1151–1167, 1999

2. Dreyer M, Pein M, Schmidt C, Heidtmann B, Schlünzen M, Rosskamp D: Comparison of the pharmacokinetics/dynamics of Gly(A21)-Arg(B31,B32)-human-insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglyacemic clamp technique (Abstract). Diabetologia 37(Suppl. 1):A78, 1994

3. Heinemann L, Linkeschova R, Rave K, Hompesh B, Sedlak M, Heise T: Time.action profile of the long-acting insulin analog glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649, 2000

4. Owens DR, Coates PA, Luzio SD, Tinbergen J, Kurzhals R: Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 23:813–819, 2000

5. Rave K, Nosek L, Heinemann L, Frick A, Becker R: Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab 29:430–431, 2003

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving Intravenous and Subcutaneous Insulin Overlap During Treatment of Diabetic Ketoacidosis: A Quality Improvement Project;Mayo Clinic Proceedings: Innovations, Quality & Outcomes;2024-06

2. Current usage of long-acting insulin analogs in patients with type 2 diabetes mellitus;Expert Review of Endocrinology & Metabolism;2024-02-20

3. The 2021–2022 position of Brazilian Diabetes Society on insulin therapy in type 1 diabetes: an evidence-based guideline to clinical practice;Diabetology & Metabolic Syndrome;2022-12-12

4. A Multi-Agent Approach Used to Predict Long-Term Glucose Oscillation in Individuals with Type 1 Diabetes;Applied Sciences;2022-09-26

5. Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs;Diabetes, Obesity and Metabolism;2020-10-19